Loading company…
Boston biopharmaceutical company developing and commercializing oncology therapies, including BIZENGRI and LEUKINE.
Partner Therapeutics, Inc. develops and commercializes biopharmaceutical products, mainly for oncology, with flagship products BIZENGRI (zenocutuzumab-zbco), for NRG1+ cancers, and LEUKINE (sargramostim), for patients exposed to myelosuppressive radiation doses. It sells to healthcare providers, hospitals and research institutions, mainly in the United States and Europe. Founded in 2017 and headquartered in Boston, US, it received USD 60 mn in Series A funding in February 2018 from investors including Adams Street Partners, MidCap Financial and Perceptive Advisors.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in